Reni Benjamin
Stock Analyst at JMP Securities
(1.49)
# 3,254
Out of 4,847 analysts
191
Total ratings
39.62%
Success rate
-12.97%
Average return
Main Sectors:
Stocks Rated by Reni Benjamin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INBX Inhibrx Biosciences | Reiterates: Market Perform | n/a | $13.14 | - | 10 | May 15, 2025 | |
| BCYC Bicycle Therapeutics | Maintains: Market Outperform | $26 → $22 | $8.50 | +158.82% | 14 | May 2, 2025 | |
| CUE Cue Biopharma | Reiterates: Market Outperform | $2 | $0.67 | +199.40% | 5 | Apr 2, 2025 | |
| BCAB BioAtla | Maintains: Market Outperform | $5 → $1 | $0.54 | +85.84% | 9 | Mar 31, 2025 | |
| ALLO Allogene Therapeutics | Upgrades: Market Outperform | $5 | $1.27 | +293.70% | 7 | Mar 14, 2025 | |
| INCY Incyte | Reiterates: Market Perform | n/a | $65.25 | - | 28 | Mar 11, 2025 | |
| ACET Adicet Bio | Reiterates: Market Perform | n/a | $0.75 | - | 5 | Mar 7, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Market Outperform | $125 | $127.65 | -2.08% | 21 | Mar 3, 2025 | |
| HOWL Werewolf Therapeutics | Maintains: Market Outperform | $12 → $4 | $1.24 | +222.58% | 5 | Jan 14, 2025 | |
| CGEN Compugen | Maintains: Market Outperform | $8 → $4 | $1.59 | +151.57% | 1 | Aug 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $2.43 | - | 4 | Nov 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.14 | - | 2 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.02 | - | 3 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $20 → $16 | $0.28 | +5,653.33% | 1 | Oct 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $10 | $20.17 | -50.42% | 2 | Oct 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $30.18 | - | 2 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $40 | $17.36 | +130.41% | 4 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $1.31 | - | 7 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.76 | - | 11 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $0.91 | +339.51% | 5 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $28 | $6.28 | +345.86% | 10 | Apr 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Outperform | $5 | $2.19 | +128.31% | 5 | Mar 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.91 | - | 10 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $8 | $6.34 | +26.28% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $60 | $63.38 | -5.33% | 1 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $9.29 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $315 | $246.43 | +27.83% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $82.93 | - | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $265 | $241.08 | +9.92% | 1 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $28 → $17 | $3.25 | +423.08% | 3 | Nov 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.37 | - | 3 | Nov 15, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | n/a | $10.13 | - | 4 | Jun 14, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Market Perform | n/a | $1.42 | - | 2 | Feb 7, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $22 → $12 | $36.04 | -66.70% | 1 | Sep 25, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $5.09 | - | 1 | Nov 15, 2017 | |
Inhibrx Biosciences
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $13.14
Upside: -
Bicycle Therapeutics
May 2, 2025
Maintains: Market Outperform
Price Target: $26 → $22
Current: $8.50
Upside: +158.82%
Cue Biopharma
Apr 2, 2025
Reiterates: Market Outperform
Price Target: $2
Current: $0.67
Upside: +199.40%
BioAtla
Mar 31, 2025
Maintains: Market Outperform
Price Target: $5 → $1
Current: $0.54
Upside: +85.84%
Allogene Therapeutics
Mar 14, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $1.27
Upside: +293.70%
Incyte
Mar 11, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $65.25
Upside: -
Adicet Bio
Mar 7, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $0.75
Upside: -
Blueprint Medicines
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $125
Current: $127.65
Upside: -2.08%
Werewolf Therapeutics
Jan 14, 2025
Maintains: Market Outperform
Price Target: $12 → $4
Current: $1.24
Upside: +222.58%
Compugen
Aug 8, 2022
Maintains: Market Outperform
Price Target: $8 → $4
Current: $1.59
Upside: +151.57%
Nov 12, 2020
Upgrades: Market Perform
Price Target: n/a
Current: $2.43
Upside: -
Dec 3, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.14
Upside: -
Jun 14, 2019
Reinstates: Market Perform
Price Target: n/a
Current: $7.02
Upside: -
Oct 22, 2018
Maintains: Outperform
Price Target: $20 → $16
Current: $0.28
Upside: +5,653.33%
Oct 12, 2018
Maintains: Outperform
Price Target: $11 → $10
Current: $20.17
Upside: -50.42%
Jun 2, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $30.18
Upside: -
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $40
Current: $17.36
Upside: +130.41%
May 15, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $1.31
Upside: -
May 9, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $1.76
Upside: -
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $0.91
Upside: +339.51%
Apr 29, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $6.28
Upside: +345.86%
Mar 18, 2025
Upgrades: Market Outperform
Price Target: $5
Current: $2.19
Upside: +128.31%
Mar 14, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $0.91
Upside: -
Mar 12, 2025
Maintains: Market Outperform
Price Target: $7 → $8
Current: $6.34
Upside: +26.28%
Mar 3, 2025
Reiterates: Market Outperform
Price Target: $60
Current: $63.38
Upside: -5.33%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $9.29
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $315
Current: $246.43
Upside: +27.83%
Feb 6, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $82.93
Upside: -
Feb 6, 2025
Reiterates: Market Outperform
Price Target: $265
Current: $241.08
Upside: +9.92%
Nov 10, 2020
Downgrades: Outperform
Price Target: $28 → $17
Current: $3.25
Upside: +423.08%
Nov 15, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $0.37
Upside: -
Jun 14, 2019
Reinstates: Outperform
Price Target: n/a
Current: $10.13
Upside: -
Feb 7, 2019
Upgrades: Market Perform
Price Target: n/a
Current: $1.42
Upside: -
Sep 25, 2018
Downgrades: Outperform
Price Target: $22 → $12
Current: $36.04
Upside: -66.70%
Nov 15, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $5.09
Upside: -